RxDoctor Payments Data

Smita Patel, MD

Family Medicine · Granger, INNPI 1518180512

Payments from drug & device makers

$1,474in general payments, 2019–2025

Across 82 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$422
  • AstraZeneca$164
  • Merck$109
  • Lilly USA, LLC$89
  • Boehringer Ingelheim$87
  • Abbott$84
  • plus $518 from 14 others

What the payments were for

  • Food & beverage$1,45599%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,474 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$136,832
Medicare patients
200
Services billed
4,226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$78,864
MounjaroTirzepatide42$49,157
FarxigaDapagliflozin Propanediol48$47,464
JanuviaSitagliptin Phosphate38$41,236
RybelsusSemaglutide15$39,016
EliquisApixaban41$33,616
JanumetSitagliptin Phos/Metformin Hcl23$27,846
TrulicityDulaglutide12$23,998
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$23,321
Spiriva HandihalerTiotropium Bromide24$22,680
ArexvyRsvpref3 Antigen/As01e/Pf62$19,194
ShingrixVaricella-Zoster Ge/As01b/Pf82$18,096
JardianceEmpagliflozin11$16,718
VyvanseLisdexamfetamine Dimesylate23$8,805
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$7,974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$39$117,88069 claims
Lilly USA, LLCMounjaro, Trulicity$89$73,15554 claims
MerckJanuvia, Janumet$109$69,08261 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$69$60,612164 claims
AstraZenecaFarxiga, Symbicort$164$55,14661 claims
Boehringer IngelheimJardiance$87$16,71811 claims
AbbVieSynthroid$422$2,12440 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Granger

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →